Abstract
Intrathecal baclofen therapy (ITB) is an established treatment for intractable spasticity. More than 1,100 patients have undergone ITB in Japan, and there are about 50 hereditary spastic paraplegia (HSP) The features of ITB in HSP are 1. small doses of baclofen may often be enough, 2. small changes of doses later the symptoms remarkably, 3. doses can be decreased after long term ITB.